The drug blocks the activity of a protein known as mammalian target of rapamycin (mTOR), which promotes proliferation through the activation of proteins such as S6 kinase. Although the mTOR ...

The research team, led by Vivek Rangnekar, Ph.D., professor and Alfred Cohen Chair in Oncology Research in the UK College of ...